<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30275858</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">1738-6756</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>21</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of breast cancer</Title>                <ISOAbbreviation>J Breast Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with <i>BRCA1/2</i> Mutations.</ArticleTitle>            <Pagination>                <MedlinePgn>297-305</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4048/jbc.2018.21.e38</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">The characteristic expression of DNA damage response proteins in familial breast cancers with <i>BRCA1</i>, <i>BRCA2</i>, or non-<i>BRCA1/2</i> mutations has not been analyzed in Chinese patients. Our study aimed to assess the differential expression of microcephalin 1 (BRIT1), ATM serine/threonine kinase (ATM), checkpoint kinase 2 (CHEK2), BRCA1, RAD51 recombinase (RAD51), and poly (ADP-ribose) polymerase 1 (PARP-1) and establish the profile of Chinese familial breast cancers with different mutation status.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We constructed five tissue microarrays from 183 familial breast cancer patients (31 with <i>BRCA1</i> mutations; 14 with <i>BRCA2</i> mutations, and 138 with non-<i>BRCA1/2</i> mutations). The DNA response and repair markers used for immunohistochemistry analysis included BRIT1, ATM, CHEK2, <i>BRCA1</i>, RAD51, and PARP-1. The expressions of these proteins were analyzed in <i>BRCA1/2</i> mutated tumors. The association between pathologic characteristics with <i>BRCA1/2</i> mutation status was also analyzed.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">In familial breast cancer patients, <i>BRCA1</i> mutated tumors were more frequent with high nuclear grade, estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 negative, low Ki-67, and positive CK5/6. <i>BRCA1</i> mutated tumors had lower CHEK2 and higher cytoplasmic BRIT1 expression than <i>BRCA2</i> and non-<i>BRCA1/2</i> mutation tumors. <i>BRCA2</i>-associated tumors showed higher CHEK2 and cytoplasmic RAD51 expression than those in other groups. Nuclear PARP-1 expression in <i>BRCA1/2</i>-associated tumors was significantly higher than in non-<i>BRCA1/2</i> mutation tumors. Moreover, we found quite a few of negative PARP-1 expression cases in <i>BRCA1/2</i> mutated groups.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">The clinicopathologic findings of BRCA1-associated Chinese familial breast cancers were similar to the results of other studies. Chinese familial breast cancer patients with <i>BRCA1/2</i> mutations might have distinctive expression of different DNA damage response proteins. The reduced expression of PARP-1 in Chinese <i>BRCA1/2</i> mutated breast cancer patients could influence the therapeutic outcome of PARP-1 inhibitors.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Zhu</LastName>                    <ForeName>Xinyi</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tian</LastName>                    <ForeName>Tian</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ruan</LastName>                    <ForeName>Miao</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rao</LastName>                    <ForeName>Jia</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Wentao</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cai</LastName>                    <ForeName>Xu</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Menghong</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Tissue Bank, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qin</LastName>                    <ForeName>Guangqi</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Tissue Bank, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Zhonghua</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Jiong</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shao</LastName>                    <ForeName>Zhimin</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shui</LastName>                    <ForeName>Ruohong</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Zhen</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>J Breast Cancer</MedlineTA>            <NlmUniqueID>101314183</NlmUniqueID>            <ISSNLinking>1738-6756</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell. 2001 Feb;7(2):273-82</RefSource>                <PMID Version="1">11239456</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Pathol. 1995 Sep;48(9):876-8</RefSource>                <PMID Version="1">7490328</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2002 Jan 25;108(2):171-82</RefSource>                <PMID Version="1">11832208</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Carcinogenesis. 2000 Feb;21(2):147-51</RefSource>                <PMID Version="1">10657950</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 1998 Dec 17;17(24):3169-76</RefSource>                <PMID Version="1">9872332</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 Oct 20;23(30):7503-11</RefSource>                <PMID Version="1">16234517</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Hum Genet. 2002 Aug;71(2):432-8</RefSource>                <PMID Version="1">12094328</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2015 Apr 30;10(4):e0125571</RefSource>                <PMID Version="1">25927356</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Cell Biol. 2010 May;20(5):269-76</RefSource>                <PMID Version="1">20299221</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2011 Jun;127(3):639-48</RefSource>                <PMID Version="1">20632086</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2009 Jul 9;361(2):123-34</RefSource>                <PMID Version="1">19553641</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2010 Jul 24;376(9737):235-44</RefSource>                <PMID Version="1">20609467</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncology (Williston Park). 2010 Jan;24(1):55-62</RefSource>                <PMID Version="1">20187322</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2016 Jan 1;138(1):110-20</RefSource>                <PMID Version="1">26205471</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2008 Jun 26;27(28):3977-85</RefSource>                <PMID Version="1">18317453</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2002 Feb 15;20(4):994-9</RefSource>                <PMID Version="1">11844822</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2005 Jul 15;11(14):5175-80</RefSource>                <PMID Version="1">16033833</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2003 Oct 24;302(5645):643-6</RefSource>                <PMID Version="1">14576434</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2007 Oct 1;6(19):2344-7</RefSource>                <PMID Version="1">17700066</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2000 Mar 9;404(6774):201-4</RefSource>                <PMID Version="1">10724175</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2005;7(1):R93-100</RefSource>                <PMID Version="1">15642173</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2002 May 1;20(9):2310-8</RefSource>                <PMID Version="1">11981002</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28</RefSource>                <PMID Version="1">16829982</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Pathol. 2013 Jul;66(7):607-12</RefSource>                <PMID Version="1">23486608</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2011 Jun;127(3):861-9</RefSource>                <PMID Version="1">21409392</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Histol Histopathol. 2009 Jan;24(1):69-76</RefSource>                <PMID Version="1">19012246</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2015 Feb;150(1):81-90</RefSource>                <PMID Version="1">25690937</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2008 Apr 10;27(17):2501-6</RefSource>                <PMID Version="1">17982490</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 1999 Jun;5(6):1249-61</RefSource>                <PMID Version="1">10389907</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neoplasia. 2014 Nov 20;16(11):982-91</RefSource>                <PMID Version="1">25425972</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BRCA1 genes</Keyword>            <Keyword MajorTopicYN="N">BRCA2 genes</Keyword>            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">DNA repair</Keyword>            <Keyword MajorTopicYN="N">Poly (ADP-ribose) polymerase-1</Keyword>        </KeywordList>        <CoiStatement>CONFLICT OF INTEREST: The authors declare that they have no competing interests.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30275858</ArticleId>            <ArticleId IdType="doi">10.4048/jbc.2018.21.e38</ArticleId>            <ArticleId IdType="pmc">PMC6158157</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>